Page 8 - Indian Pharma Companies

Covid-19: Remdesivir production scaled up to 11.9 million vials per month

All seven domestic licensed manufacturers of Remdesivir have scaled up production from 3.8 million vials per month to nearly 11.9 million vials per month, following government directives

Dr Reddy's Laboratories consolidated net profit dips 29% to Rs 557 crore

Dr Reddy's Laboratories on Friday reported 29 per cent decline in consolidated net profit at Rs 557 crore for the fourth quarter ended March 31, 2021. The Hyderabad-based drug major had posted a net profit of Rs 781 crore in January-March period of 2019-20. Net sales however rose to Rs 4,608 crore in the quarter under review as compared with Rs 4,336.1 crore in the fourth quarter of 2019-20, Dr Reddy's Laboratories said in a regulatory filing. For 2020-21 fiscal year, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20. Net sales increased to Rs 18,420 crore during the last fiscal year as compared with Rs 16,357 crore in 2019-20. "In FY 21, we continued to grow across all our businesses, enhance productivity and strengthen our development pipeline," Dr Reddy's Laboratories Co-Chairman and MD G V Prasad said. The company is prioritising its efforts to launch Sputnik V vaccine across India while working on the development and ...

Eli Lilly signs licensing pact with Cipla, Sun, Lupin for Covid-19 drug

Olumiant, or Baricitinib, is an oral drug developed by US biopharmaceutical major, Incyte Corporation, and licensed to Eli Lilly

Serum, Bharat Biotech to get suppliers' credit for 300 mn Covid-19 doses

Govt okays Rs 4,500 cr upfront payment for 300 mn doses

Mankind Pharma eyes 50% revenue from chronic therapy drugs in 3 years

With the launch, the company has become the first Indian and second global firm to develop the drug, which is a generic version of Abbott's Duphaston

Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh

Access to the private market, international sales are other factors that will impact margins

Remdesivir output to be ramped up as Covid-19 cases rise sharply

Zydus had recently also slashed prices of its remdesivir brand Remdac to Rs 899 per dose

Dr Reddy's expects Covid vaccine to get nod from India in next few weeks

Pharma major Dr Reddy's Laboratories expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said

Adar Poonawalla rents London mansion for $69,000 a week, says report

The mansion is one of the largest residences in the neighborhood and measures about 25,000 square feet (2,322 square meters), the equivalent of about 24 average English homes

Covaxin manufacturing may get a booster shot as demand for vaccines grows

Bharat Biotech also has another site at Bengaluru that is currently making vaccines other than Covaxin

Clinically tried and tested: Bharat Biotech boss Ella wins Covaxin fight

Covaxin was India's first indigenously developed vaccine to be approved, controversially under "clinical trial mode" in the first week of January

European Union drug regulator audits manufacturing site of Serum Institute

AstraZeneca Chief Executive (CEO) Pascal Soriot has indicated that the company may look at factories outside of the EU to meet the supply commitments.

Healing a weak regulator

Weaknesses in India's drug regulatory regime and the constraints and questionable decisions of the drug regulator could mar the country's reputation in global markets

India's economic revival: PLI scheme likely to take center stage

16 schemes from equal numbers of companies have been approved to boost local production, value addition and, consequently, export of mobile phones.

Bharat Biotech to have phase 3 efficacy data for Covaxin in 2 weeks

The restricted emergency use allowed by the regulator was based on phase 2 safety and immunogenicity studies, as well as data from monkey trials

Serum Institute to export Covid-19 vaccine to 25-30 countries on Tuesday

Bharat Bio says keen to follow, have capacity of 40 mn doses a month

Dr Reddy's applies for emergency use approval for Sputnik V vaccine

Aims to launch the vaccine in March if regulator approval comes through

Covid-19 drugs among top-selling brands for pharma players in India

Data shows that cumulative sales of remdesivir was Rs 510 crore in January 2021, while for favipiravir it was Rs 471 crore

PLI scheme may trigger investments worth Rs 50,000 crore into pharma sector

According to the people, 86 companies have applied to start production of bulk drugs listed under the PLI scheme so far, said sources

Sales of Ivermectin, drug to treat parasitic infections, jump fourfold

Mumbai-based pulmonologist Dr Agam Vora said in the first few months of the pandemic, the line of treatment was not established